It is a Reservation of Rights, it won't delay the sale. It seems like a smart, precautionary move.
You have to remember that Mitsui already cut BioAmber a break in 2017. Mitsui's divestiture of their equity stake in the Sarnia Plant joint venture was for $1. This decision followed, what was released as, "a review of corporate strategy". Of course, this also allowed Mitsui to negotiate better terms for the marketing and distribution of BioAmber's bio-succinic. They kept 1.3M shares and currently still hold them.
SS